- Home
- PTGX vs SRRK Comparison
PTGX vs SRRK Comparison
Compare PTGX & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | SRRK |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PTGX | SRRK |
|---|---|---|
| Price | $89.29 | $45.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $86.44 | $47.00 |
| AVG Volume (30 Days) | 886.1K | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $209,217,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $296.47 | $20,271.77 |
| P/E Ratio | $124.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.70 | $22.71 |
| 52 Week High | $93.25 | $46.98 |
Technical Indicators
Market Signals| Indicator | PTGX | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 69.88 |
| Support Level | $83.52 | $39.51 |
| Resistance Level | $90.85 | $43.94 |
| Average True Range (ATR) | 2.63 | 2.25 |
| MACD | -0.33 | 0.56 |
| Stochastic Oscillator | 83.62 | 91.11 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.